|
|
Nano Drug DeliveryPublished by: Drug and Market Development Publishing Published: Apr. 1, 2005 - 154 Pages Table of ContentsExecutive Summary E.1 Introduction E.2 Driving Forces⎯A Convergence of Nanotech and Drug Delivery E.2.1 Industrial and Financial Drivers E.2.2 Technological Drivers E.2.3 Government and Social Drivers E.2.4 Industry Challenges E.3 Brief Summary of Market Opportunities and Challenges. E.3.1 Dosing E.3.2 Drug Formulation E.3.3 Imaging Agents E.3.4 Implantable (Surgical) Delivery Systems E.3.5 Injectable Delivery Systems E.3.6 Microneedle Systems E.3.7 Oral Delivery Systems. E.3.8 Targeted Delivery and Release E.3.9 Topical Delivery Systems E.3.10 Toxin Removal E.3.11 Transdermal Systems E.3.12 Factors Holding Back the Market E.3.13 Regulatory/Long-term Health Risk E.3.14 Competitive Risk E.3.15 Financing⎯Early Stage E.3.16 Financing⎯Public Markets E.3.17 Scale-up. E.3.18 Technical Challenges. E.3.19 Drug Delivery Outsourcing Chapter One Introduction. 1.1 Background to Report 1.2 Objectives of this Report 1.3 Scope of Report 1.3.1 Research Methodology and Information Sources 1.4 Plan of Report Chapter Two Nanotechnology-Based Drug Delivery Technologies 2.1 Introduction 2.2 Advantages of Nano-Engineered Drug Delivery Systems 2.2.1 Ability to Cross Blood-Brain Barrier and Other Critical Systems 2.2.2 Localized Delivery⎯Greater Dosing Efficiency of Active Agents 2.2.3 Stabilization and Solubility 2.2.4 Surface Area 2.2.5 Sustained Delivery⎯Enhances Time-Release Function 2.2.6 Genomic Targeting and Gene Delivery 2.3 Overview of Commercially Available Nanotech Products in Drug Delivery, and Pending Applications 2.3.1 Dendrimers 2.3.2 Encapsulation Technologies, Coatings, Hermetic Sealants 2.3.3 Implantable Delivery Methods 2.3.4 Lipid Nanoparticles 2.3.5 External Targeting and Activation Methods for Nanoparticles: Magnetic, Ultrasound, and Radio Frequency 2.3.6 Nanotubes and Fullerenes 2.3.7 Nasal Delivery Methods 2.3.8 Pulmonary Delivery Methods 2.3.9 Quantum Dots 2.3.10 Sensors and Biomarkers 2.3.11 Cancer Therapeutics 2.3.12 Transdermal Systems Chapter Three The Commercialization Process ⎯Factors in Taking a Nano-Enabled Drug Delivery System to Market 3.1 Introduction and Business Climate 3.2 Nanotech’s Place in the Pharmaceutical Value Chain 3.3 Venture Capital Environment 3.4 Extension of Patent and or Product Life. 3.5 Intellectual Property Overlap and Potential Litigation 3.6 The Environment for Mergers and Acquisitions Chapter Four Geographic Considerations for Nano-Enabled Drug Delivery Systems 4.1 United States 4.1.1 Brief Summary of Value Chain 4.1.2 Distributors / Wholesale 4.1.3 Retail 4.1.4 Patenting and Regulatory Concerns 4.2 Canada 4.2.1 Brief Summary of Value Chain and Nanotech Initiatives 4.2.2 Patenting and Regulatory Concerns 4.3 Europe 4.3.1 Brief Summary of Value Chain and Nanotech Initiatives 4.3.2 Distributors / Wholesale 4.3.3 Patenting and Regulatory Concerns 4.4 Japan 4.4.1 Brief Summary of Value Chain and Nanotech Initiatives 4.4.2 Patenting and Regulatory Concerns . 4.5 Israel 4.5.1 Summary of Value Chain 4.5.2 Patenting and Regulatory Concerns 4.6 Other Countries . 4.6.1 Summary 4.6.2 Patenting and Regulatory Concerns 4.6.3 The China Factor 4.6.4 The India Factor. Chapter Five Eight-Year Market Forecasts 5.1 Forecasting Methodology 5.2 Overall Findings and Timeline for Development 5.2.1 Overall Drug Delivery Market . 5.2.2 Nanotechnology-Enabled Drug Delivery Market 5.3 Forecasts by Application Type. 5.3.1 Biomarker and Imaging Agents 5.3.2 Cancer Therapeutics.. 5.3.3 Dendrimers 5.3.4 Gene and Vaccine Delivery 5.3.5 Implantable Methods. 5.3.6 Injectable and Needle-Free 5.3.7 Lipid Nanoparticles 5.3.8 Magnetic, Ultrasound, and other External Targeting Methods 5.3.9 Nanotubes and Fullerenes 5.3.10 Nasal Delivery Methods 5.3.11 Oral Delivery Methods 5.3.12 Polymeric Delivery Methods. 5.3.13 Pulmonary Delivery Methods 5.3.14 Topical Delivery Systems 5.3.15 Transdermal Systems Appendix A. List of Acronyms and Abbreviations Used in This Report Appendix B Contact Information for Key Firms in Nano-Enabled Drug Delivery About the Author AbstractThis report examines the business opportunities that are being created by nano-engineered solutions for the drug delivery market. According to one source, approximately $65 billion in drug revenues every year are accounted for by pharmaceuticals with poor bio-availability which far too often results in higher patient costs and inefficient treatment but also, more importantly, increased risks of toxicity or even death. Because nanotechnology focuses on the very small it is uniquely suited to creating systems that can better deliver drugs to tiny areas within the body. Nano-enabled drug delivery also makes it possible for drugs to permeate through cell walls, which is of critical importance to the expected growth of genetic medicine over the next few years. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||